М
Anonymous
Dec 19, 2019
Consultation with an orthopedist (traumatologist)
Patient Safety
Patient Safety
Jesus Soberino
Clinical oncologist
Melanoma Unit, IOB Institute of Oncology
This doctor has experience in endocrine treatment, collaborating on studies aimed at overcoming resistance to hormone therapy. They have also been involved in numerous phase 1, 2 and 3 studies in breast and melanoma, which have led to the approval of new drugs in new indications. Their main area of interest lies in immunotherapy for melanoma treatment and patient care. They have participated in trials that have led to the approval of cdk4/6 palbociclib and ribociclib inhibitors in the first line of metastatic breast cancer, and Pembrolizumab in the first line of metastatic melanoma, as well as the combination of Nivolumab and Ipilimumab. They are a member of the Breast Cancer Unit and Melanoma Unit at the Vall d'Hebron University Hospital and the Vall d'Hebron Institute of Oncology. This doctor is an experienced oncologist with expertise in breast cancer and melanoma treatments, including endocrine therapy, immunotherapy, and patient care. They have been involved in numerous clinical trials leading to the approval of new drugs in new indications.
Certification & Accreditation
Vall d'Hebron Institute of Oncology
His main areas of interest lie in the breast cancer field, in endocrine treatment, collaborating on studies aimed at overcoming resistance to hormone therapy that may occur both during adjuvant therapy and in metastatic disease.
He has participated as a researcher in numerous phase 1, 2 and 3 studies, both in breast and melanoma, some of which have led to the approval of new drugs in new indications. He continues to work actively with other groups to drive the development of new drugs to help improve results in this patient group.
In the field of melanoma, his main area of interest is centered on immunotherapy treatment.
And along with all of the above there is patient care, always maintaining a holistic view of the patient, taking an interest in all the details that can happen in the evolution of their illness.
Career
- Participant in trials that have led to the approval of cdk4/6 palbociclib and ribociclib inhibitors in the first line of metastatic breast cancer, as well as in developing trials for adjuvant disease.
- Participant in the studies that led to the approval of Pembrolizumab in the first line of metastatic melanoma, as well as the combination of Nivolumab and Ipilimumab, both of which revolutionized the treatment of this disease.
- Member of the Breast Cancer Unit and Melanoma Unit of the Vall d’Hebron University Hospital and the Vall d’Hebron Institute of Oncology (VHIO).
Procedures performed by the doctor
Patient reviews
Who knows more about the doctor, amenities, and hospital staff than someone who has checked everything themselves? We collect the genuine experiences of our patients for you to make the best choice.
Each review belongs to a verified customer after getting medical services booked via Bookimed.com.
We publish positive and negative reviews, moderated for compliance with Reviews & Comments Policy.
F
Fatima
May 15, 2019
Knee replacement
The easiest way of finding you best doctor
М
Anonymous
Dec 19, 2019
Consultation with an orthopedist (traumatologist)
Н
Надежда Sergiyenko
Jun 11, 2019
Ovarian cancer
The format is quite simple, everything is accessible and understandable, the doctor is very qualified. I will not say that we talked about clinical studies, there was no definitive information. We are... Read more
F
Fatima
May 15, 2019
Knee replacement
Н
Надежда Sergiyenko
Jun 11, 2019
Ovarian cancer
I really liked the specialist himself, a very good-natured man without pathos, n